Abstract 3985
Background
Oral cavity and oropharyngeal squamous cell cancers (OC-OPSCC) display high cancer mortality. Aspiration, infection, other complications or treatment, and age- and substance-related comorbidities contribute to non-cancer mortality. This single-institution study examines cause of death in patients treated for OC-OPSCC with brachytherapy, chemotherapy, external beam radiation, surgery, or combination of modalities. We hypothesize that brachytherapy results in lower non-cancer mortality.
Methods
IRB approval was obtained. Our institution’s Tumor Registry and electronic medical record were used to identify patients with a first OC-OPSCC diagnosis between 2000-2010. Patients with a second primary cancer at diagnosis were excluded. The primary outcome was association between treatment modality and non-cancer mortality. Secondary outcomes were effects of comorbidities on death, specific causes of non-cancer mortality, and cancer mortality.
Results
Of 693 eligible patients, 460 were deceased. 84 died of the primary malignancy. Non-primary cancer cause of death was determined in 96 patients; 24 died from a second primary. 193 patients received brachytherapy. Cox proportional hazards regression was performed on treatment regimen, exposures, and non-cancer mortality, stratified by AJCC stage, race, and sex. Age, smoking, and alcohol were associated with worse survival, with HRs of 1.03 (p < 0.005), 1.36 (p < 0.11), and 2.23 (p < 0.005), respectively. Brachytherapy had a notable 0.52 HR (p < 0.005). Non-smoking OPC patients had a 76% 5-year overall survival (OS), suggesting these were largely HPV-driven cancers. In smokers with OPC, OS was 33% at 5 years, with a HR of 0.35 for brachytherapy-treated patients.
Conclusions
We report non-cancer mortality from an extensively annotated cohort of curatively treated OC-OPSCC. We show a significant correlation between receipt of brachytherapy and non-cancer survival, independent of remission status. Potential explanations include improved disease control, patient selection, and reduced exposure to external beam radiation. Although HPV status was not available, OPC in non-smokers displayed OS characteristic for HPV-associated cancer. The impact of brachytherapy in OPC was strongest in smokers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Mehra: Research grant / Funding (institution): DePuy Synthes Educational Grant for Yale Head and Neck Surgery Fellowship. B. Burtness: Advisory / Consultancy: Aduro; Advisory / Consultancy: Alligator Biosciences; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Celgene; Advisory / Consultancy: Cue Biopharma; Advisory / Consultancy: Genentech/Roche; Advisory / Consultancy: Glaxo Smith Kline; Advisory / Consultancy: IDDI; Advisory / Consultancy: Merck. All other authors have declared no conflicts of interest.
Resources from the same session
4822 - Efficiacy of different nutritional intervention on nutritional status and quality of life for local advanced nasopharyngeal carcinoma patients: a prospective clinical trial
Presenter: Yuan-yuan Chen
Session: Poster Display session 3
Resources:
Abstract
2628 - Apatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma
Presenter: Changjuan Tao
Session: Poster Display session 3
Resources:
Abstract
4887 - Impact of tumor site and adjuvant radiotherapy on survival of adenoid cystic carcinoma: a SEER database analysis
Presenter: Jason Tasoulas
Session: Poster Display session 3
Resources:
Abstract
2634 - Efficacy and safety of anlotinib for patients with recurrent and/or metastatic salivary gland carcinomas
Presenter: Wen Jiang
Session: Poster Display session 3
Resources:
Abstract
3568 - ACCURACY a phase (P) 2 trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): preliminary safety and efficacy data.
Presenter: Renata Ferrarotto
Session: Poster Display session 3
Resources:
Abstract
683 - Pathologic Staging Changes in Oral Cavity Squamous Cell Carcinoma—Stage Migration and Implications for Adjuvant Treatment
Presenter: Zain Husain
Session: Poster Display session 3
Resources:
Abstract
563 - Expression of immune response biomarkers in head and neck squamous cell carcinoma (HNSCC) in irradiated area
Presenter: Carole Pflumio
Session: Poster Display session 3
Resources:
Abstract
4030 - HLA-Ligandome analysis reveals target antigens of oropharyngeal squamous cell carcinoma
Presenter: Simon Laban
Session: Poster Display session 3
Resources:
Abstract
2979 - Topographical distribution of sentinel lymph nodes in early tongue squamous cell carcinomas
Presenter: Hiroyuki Goda
Session: Poster Display session 3
Resources:
Abstract
3517 - Role of follow-up (FU) FDG-PET/CT (FU-FDG-PET/CT) in patients with locoregionally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) treated with chemotherapy and radiotherapy (RT), either concurrent (CRT) or sequential (ST).
Presenter: Bert Van Den Heuvel
Session: Poster Display session 3
Resources:
Abstract